(Q36497045)

14 August 2017

1 reference

title

Treating HIV during pregnancy: an update on safety issues (English)

1 reference

14 August 2017

0 references

D Heather Watts

1

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

29

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

467-490

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200629060-00002

14 August 2017

exact match

0 references

cites work

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Does human immunodeficiency virus infection protect against preeclampsia-eclampsia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629060-00002

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

12 December 2020

Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.

1 reference

12 December 2020

A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators

1 reference

12 December 2020

15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. DITRAME ANRS 049 Study Group

1 reference

12 December 2020

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

12 December 2020

Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.

1 reference

12 December 2020

Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals

1 reference

12 December 2020

Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.

1 reference

12 December 2020

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

1 reference

12 December 2020

Management of human immunodeficiency virus infection in pregnancy

1 reference

12 December 2020

Pharmacokinetic disposition of zidovudine during pregnancy

1 reference

12 December 2020

Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Preven

1 reference

12 December 2020

Hepatotoxicity associated with nevirapine use.

1 reference

12 December 2020

Antiretroviral therapy during pregnancy and the risk of an adverse outcome

1 reference

12 December 2020

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe

1 reference

12 December 2020

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

1 reference

12 December 2020

Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy

1 reference

12 December 2020

Combination antiretroviral therapy and duration of pregnancy

1 reference

12 December 2020

Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy

1 reference

12 December 2020

Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study

1 reference

12 December 2020

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

1 reference

12 December 2020

Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants

1 reference

12 December 2020

Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.

1 reference

12 December 2020

The relationship of pregnancy to the use of highly active antiretroviral therapy

1 reference

12 December 2020

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

1 reference

12 December 2020

6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study G

1 reference

12 December 2020

Nevirapine resistance after single dose prophylaxis.

1 reference

12 December 2020

Riboflavine and severe lactic acidosis

1 reference

12 December 2020

From the Food and Drug Administration

1 reference

12 December 2020

Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study

1 reference

12 December 2020

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group prot

1 reference

12 December 2020

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

1 reference

12 December 2020

Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?

1 reference

12 December 2020

Pre-eclampsia, antiretroviral therapy, and immune reconstitution

1 reference

12 December 2020

Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women

1 reference

12 December 2020

Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission

1 reference

12 December 2020

Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team

1 reference

12 December 2020

A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine.

1 reference

12 December 2020

Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight?

1 reference

12 December 2020

Pharmacokinetics of indinavir in HIV-positive pregnant women

1 reference

12 December 2020

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Height, weight, and growth in children born to mothers with HIV-1 infection in Europe

1 reference

12 December 2020

Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.

1 reference

12 December 2020

Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers

1 reference

12 December 2020

Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial

1 reference

12 December 2020

Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir

1 reference

12 December 2020

Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial

1 reference

12 December 2020

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy

1 reference

12 December 2020

HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda

1 reference

12 December 2020

Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy

1 reference

12 December 2020

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

1 reference

12 December 2020

Risk factors for pediatric human immunodeficiency virus-related malignancy.

1 reference

12 December 2020

Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand

1 reference

12 December 2020

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study

1 reference

12 December 2020

Absence of Cardiac Toxicity of Zidovudine in Infants

1 reference

12 December 2020

Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

1 reference

12 December 2020

Insulin Resistance Complicating Pregnancy in a Human Immunodeficiency Virus–Infected Patient Treated With Protease Inhibitors and Corticosteroids

1 reference

12 December 2020

Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: Insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count

1 reference

12 December 2020

Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication

1 reference

12 December 2020

The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis.

1 reference

12 December 2020

18-Month mortality and perinatal exposure to zidovudine in West Africa

1 reference

12 December 2020

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

12 December 2020

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy

1 reference

12 December 2020

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial

1 reference

12 December 2020

Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

1 reference

12 December 2020

Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.

1 reference

12 December 2020

Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.

1 reference

12 December 2020

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

1 reference

12 December 2020

Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated

1 reference

12 December 2020

Preeclampsia and HIV infection

1 reference

12 December 2020

Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats

1 reference

12 December 2020

Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial

1 reference

12 December 2020

Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.

1 reference

12 December 2020

Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy

1 reference

12 December 2020

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group

1 reference

12 December 2020

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

1 reference

12 December 2020

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

1 reference

12 December 2020

Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts

1 reference

12 December 2020

Concentrations of protease inhibitors in cord blood after in utero exposure

1 reference

12 December 2020

Risk of early febrile seizure with perinatal exposure to nucleoside analogues

1 reference

12 December 2020

Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy

1 reference

12 December 2020

10.2165/00002018-200629060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1035620409

0 references

1 reference